In the 40 years since the classic study by Johnstone and colleagues,
1 schizophrenia has been understood as a disorder characterized by alterations in brain structure, with the most robust findings including ventricular enlargement and reductions in overall gray matter volume.
2 Studies of cortical thickness and surface area have also revealed consistent patterns of frontotemporal thinning in patients with chronic
3-5 and first-episode
6-10 schizophrenia. In recent years, accumulating evidence suggests that antipsychotics may contribute to observed structural brain changes, including the cortical and subcortical structures.
11,12 Some studies suggest that typical antipsychotics may be associated with more dramatic structural changes (ie, larger reductions in gray matter volume, increased caudate and putamen volume) than atypical agents,
5,13 whereas others fail to find a structural relationship with specific medications.
3,14 In addition, studies of brain volume, cortical thickness, and surface area in antipsychotic-naive
8,15 and prodromal
16 individuals reveal that structural abnormalities are present before the initiation of antipsychotic therapy. These findings suggest that antipsychotics may contribute to findings of gray matter reduction in schizophrenia, but measurable changes are also caused by the illness itself.